Fragment-based drug design of inhibitors of N.meningitidis DsbD

Multi-drug resistant bacteria represent a significant public health threat. It is critical to develop new ways to treat bacterial infections which target pathways different to those used by current drugs.

Periplasmic Disulfide Bond (Dsb) forming enzymes catalyse the oxidative folding of many toxins and surface proteins required for virulence in a range of pathogenic bacteria including meningitis and gonorrhoea. We are working to develop initial hits obtained from a screened library into higher-affinity ligands using the approach of fragment-based drug design (FBDD).